Identification and validation of plasma AGRN as a novel diagnostic biomarker of hepatitis B Virus-related chronic hepatitis and liver fibrosis/cirrhosis

Authors: Rong Ai, Lu Li, Xiwei Yuan, Dandan Zhao, Tongguo Miao, Weiwei Guan, Shiming Dong, Chen Dong, Yao Dou, Mengmeng Hou and Yuemin Nan

DOI: 10.14670/HH-18-695
Article type: ORIGINAL ARTICLE
Accepted: 2023-12-21
Epub ahead of print: 2023-12-21
Identification and validation of plasma AGRN as a novel diagnostic biomarker of hepatitis B Virus-related chronic hepatitis and liver fibrosis/cirrhosis

Rong Ai\textsuperscript{1,2*}, Lu Li\textsuperscript{1,2*}, Xiwei Yuan\textsuperscript{1,2}, Dandan Zhao\textsuperscript{1,2}, Tongguo Miao\textsuperscript{1,2}, Weiwei Guan\textsuperscript{1,2}, Shiming Dong\textsuperscript{1,2}, Chen Dong\textsuperscript{1,2}, Yao Dou\textsuperscript{1,2}, Mengmeng Hou\textsuperscript{1,2}, Yuemin Nan\textsuperscript{1,2}

\textsuperscript{1}Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, 050051 Shijiazhuang, China
\textsuperscript{2}Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, China

*These authors contributed equally to this work

Corresponding author: Yuemin Nan. Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, No. 139 Ziqiang Road, 050051 Shijiazhuang, Hebei Province, China.

Email: nanyuemin@163.com or nanyuemin@hebmu.edu.cn

Rong Ai, ORCID: 0000-0002-3647-545X, Email: airong0708@163.com
Lu Li, ORCID: 0000-0003-1078-9730, Email: liludihh@163.com
Xiwei Yuan, ORCID: 0000-0002-5257-8782, Email: yuanxiwei321@163.com
Dandan Zhao, ORCID: 0000-0002-9577-5698, Email: xietianbian@163.com
Tongguo Miao, ORCID: 0000-0002-2165-8325, Email: 18532103310@163.com
Weiwei Guan, ORCID: 0000-0003-3602-6221, Email: gww198222@126.com
Shiming Dong, ORCID: 0000-0003-3621-1443, Email: dongding00@126.com
Chen Dong, ORCID: 0000-0003-1183-5364, Email: 3523688459@qq.com
Yao Dou, ORCID: 0000-0002-1757-3193, Email: dy2546158724@163.com
Mengmeng Hou, ORCID: 0000-0001-9961-8473, Email: houmengmeng163@163.com
Yuemin Nan, ORCID: 0000-0003-4192-099X, Email: nanyuemin@163.com
or nanyuemin@hebmu.edu.cn.
Abstract

Objective: The aim of this study was to find novel biomarkers and develop a non-invasive, effective diagnostic model for hepatitis B Virus-related chronic hepatitis and liver fibrosis/cirrhosis.

Method: Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to assess the expression of differentially expressed genes (AGRN, JAG1, CCL5, ID3, CCND1, and CAPN2) in peripheral blood mononuclear cells (PBMCs) from healthy subjects, chronic hepatitis B (CHB), and liver fibrosis/cirrhosis (LF/LC) patients. The molecular mechanisms underlying AGRN-regulated CHB were further explored and verified in LX2 cells, in which small interfering RNA (siRNA) was used to block AGRN gene expression. Finally, enzyme-linked Immunosorbent Assay (ELISA) was used to measure AGRN protein expression in 100 healthy volunteers, 100 CHB patients, and 100 LF/LC patients, and the efficacy of the diagnostic model was assessed by the Area Under the Curve (AUC).

Results: AGRN mRNA displayed a steady rise in the PBMCs of normal, CHB, and LF/LC patients. Besides, AGRN expression was markedly elevated in activated LX2 cells, whereas the expression of COL1 and α-SMA decreased when AGRN was inhibited using siRNA. In addition, downregulation of AGRN can reduce the gene expression of β-catenin and c-MYC while upregulating the expression of GSK-3β. Furthermore, PLT and AGRN were used to develop a non-invasive diagnostic model (PA). To identify CHB patients from healthy subjects, the AUC of the PA model was 0.951, with a sensitivity of 87.0% and a specificity of 91.0%. The AUC of the PA model was 0.922 with a sensitivity of 82.0% and a specificity of 90.0% when differentiating between LF/LC and CHB patients.

Conclusion: The current study indicated that AGRN could be a potential plasma biomarker and the established PA model could improve the diagnostic accuracy for HBV-related liver diseases.

Keywords: biomarker, HBV-associated liver diseases, chronic hepatitis B, liver fibrosis/cirrhosis, AGRN

Introduction

Chronic hepatitis B (CHB) is an overlying inflammatory liver disease due to persistent hepatitis B virus (HBV) infection, which is a major public health issue worldwide. Studies have indicated that the persistence or recurrence of inflammatory necrosis gives rise to the development of CHB in individuals with chronic HBV infection. CHB could gradually progress to liver fibrosis, cirrhosis, and even hepatic carcinoma (Lok et al., 2007). However, the pathophysiology of chronic HBV infection has not yet been fully understood (Bertoletti et al., 2012; Cornberg et al., 2017). HBV induces hepatocellular lesions through specific immune reactions and cytokine release, rather than via direct viral damage or insufficient immune response (Shih et al., 2018; Sarmati et al., 2019). Excessive extracellular matrix (ECM) deposition in response to liver injury leads to liver fibrosis, which serves as a compensatory response to chronic liver damage (Bataller et al., 2005). Recent studies have shown that liver fibrosis and cirrhosis are
dynamic and potentially reversible (Masatsugu et al., 2018). Accordingly, the precise
diagnosis of liver fibrosis/cirrhosis is essential for improving the prognosis of CHB,
preventing complications, and reducing the mortality and disease burden associated with
HBV infection (Kim et al., 2012; Lo et al., 2017).

Presently, the gold standard for diagnosing liver fibrosis/cirrhosis is pathological
histological assessment, which, due to its invasive nature, imposes limitations on its
clinical application. (Kose et al., 2015). In consequence, non-invasive indices such as
aminotransferase-to-platelet ratio (APRI) and fibrosis-4 (FIB-4) are commonly used to
predict liver fibrosis/cirrhosis in chronic viral hepatitis (Sterling et al., 2006; Xiao et al.,
2014). Due to advancements in molecular biology, biomarkers play a crucial role in the
early diagnosis and monitoring of various diseases. Some recent clinical studies have
focused on identifying valuable biomarkers to assess HBV-related hepatic disorders (Jin
et al., 2015; Wu et al., 2015).

Our previous research revealed that transcriptome sequencing (RNA-Seq) analysis
of liver tissues from healthy volunteers, CHB patients, and liver fibrosis/cirrhosis
(LF/LC) patients identified 348 differentially expressed genes exhibiting a progressively
increasing trend across those three cohorts. In this study, we performed GO/KEGG
pathway enrichment analysis and identified six genes (AGRN, JAG1, CCL5, ID3,
CCND1, CAPN2) closely associated with CHB and LF pathways, which were
subsequently investigated as potential biomarkers. By comparing the differential
expression of the six genes between LF/LC patients, CHB patients, and healthy controls
and exploring the mechanism in vitro, AGRN was identified as a new biomarker for
predicting the progression of HBV-associated hepatic diseases.

Materials and methods

Study Population

Our study is a single-center cross-sectional study. Blood samples were taken from
100 CHB patients and 100 LF/LC patients who were admitted to the Department of
Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical
University from January 2020 to December 2021. The control group consisted of 100
healthy individuals who were admitted for physical examinations in the same period.
Inclusion criteria were as follows: (1) Adult patients (>18 years); (2) Diagnosed based
on widely accepted clinical guidelines for CHB and LF/LC; (3) Child-Pugh score <7
(grade A); (4) Willing to give written informed consent. Exclusion criteria were as
follows: (1) Co-infection with human immunodeficiency virus (HIV) or other
hepatotropic viruses; (2) Decompensated cirrhosis; (3) Chronic liver disease from other
causes; (4) Complicated with severe cardiovascular, pulmonary, or renal diseases, or
malignant tumors. Patients’ basic clinical information and laboratory results were
collected. All procedures were performed after Ethical approval by the Ethics Committee
of the Third Hospital of Hebei Medical University. Following centrifugation at 1,000 g
for 5 min, the serum was extracted and kept at -80°C. From each group, 20 serum samples
were randomly chosen for peripheral blood mononuclear cell (PBMC) extraction.
PBMCs were quickly separated and kept at -80°C.
Cell culture

LX2 (human hepatic stellate cell line) was obtained from Shanghai Cell and Molecular Biology Research Center. LX2 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) medium with 10% Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin solution in an incubator set to 37°C and 5% CO₂.

Cell stimulation by TGF-β1

LX2 cells were cultured in 6-well plates at a density of 3×10⁵ cells/well with 2 ml of Complete Growth Medium at the beginning of the process. Serum-free Media was used once cell confluence reached about 60%. After 1h, recombinant human TGF-β1 was added at final concentrations of 2 ng/ml, 5 ng/ml, and 10 ng/ml, respectively. Both TGF-β1 treated cells and untreated control cells were collected after 48h. In addition, cells treated with 10 ng/ml of TGF-β1 were harvested after 12, 24, and 48h.

Cell transfection

LX2 cells were seeded in 6-well plates the day before transfection. When cell confluence reached 30-50%, small-interfering RNAs (siRNAs) were transfected via Lipofectamine™ 2000 (Invitrogen), according to the manufacturer’s recommendations. Serum-free media was replaced 6 h after transfection and the cells were cultured in a cell incubator. Three siRNAs were designed against AGRN, and a non-targeting control siRNA (NC-siRNA) was employed as a negative control (all synthesized by Shanghai GenePharma, Co., Ltd). SiRNA sequences are shown in Table 1. Lipofectamine™ 2000 was used as a positive transfection control. A null group was incubated under normal conditions without siRNA transfection. The final concentration of siRNA was 30 nM. TGF-β1 was added 24h later. Transfected cells were harvested 48h later.

RNA extraction and quantitative real-time PCR

Total RNA was extracted from PBMCs of the three groups and LX2 cells using TRIzol (Invitrogen). For reverse transcription, the PrimeScript RT reagent Kit with gDNA Eraser (TaKaRa, Dalian, China) was used according to the instructions of the manufacturer. The reverse transcription procedure was carried out at 37°C for 15 minutes, then at 85°C for 5 seconds; cDNA samples were kept at -20°C.

The following thermocycling parameters were used in the amplification reactions using TB Green Premix Ex Taq II (TaKaRa, Dalian, China) on the ABI 7500 Real-Time quantitative PCR System: 95°C for 30 sec; followed by 40 cycles of 95°C for 5 sec and 60°C for 34 sec. The primer sequences used are listed in Table 1. Gene expression was compared to GAPDH as a reference. The biological and technical duplicates of each sample were repeated three times on a single plate. The 2⁻ΔΔCT approach was utilized to calculate relative gene expression (Livak et al., 2001).
Enzyme-linked Immunosorbent Assay (ELISA)

The levels of plasma AGRN were determined using an ELISA kit from Shanghai Zcibio Biotechnology Co. Ltd. All procedures were performed following the manufacturer's instructions.

Statistical Analysis

Baseline characteristics are presented using descriptive statistics with mean or median for continuous variables and numbers or frequencies (%) for categorical variables. Normality and homogeneity of variance for continuous variables were tested using Shapiro-Wilk and Levene’s tests, respectively. Differences between groups were assessed using parametric (LSD or t-test) and nonparametric (Kruskal-Wallis or Mann-Whitney U) statistics for continuous variables, and χ² tests for categorical variables. Univariate and multivariate logistic regression models were applied. The diagnostic accuracy was evaluated using the Receiver Operating Characteristics Curve (ROC). All statistical analyses were performed using GraphPad Prism 9.0, MedCalc 15.0, and SPSS 26.0. Differences were considered significant when the P value < 0.05.

Results

**AGRN, JAG1, CCL5, ID3, CCND1, and CAPN2 mRNA expression levels in human PBMCs**

The expression of *AGRN, JAG1, CCL5, ID3, CCND1, and CAPN2* mRNAs in human PBMCs was detected by quantitative real-time PCR (qRT-PCR) (Fig. 1A). Consistent with the results of RNA-Seq, the expression levels of the six genes were all higher in the CHB group than in the control group. Of these, *AGRN, JAG1, ID3, and CAPN2* were significantly upregulated (*P<0.05, **P<0.01). *JAG1* mRNA levels in the LF/LC group were greater than in CHB but the difference was not statistically significant. However, the expression of *CCL5, ID3, CCND1, and CAPN2* were downregulated in the LF/LC group. Only the expression of *AGRN* significantly increased in all three groups (*P<0.05, **P<0.01). These findings suggest that AGRN might be implicated and meaningful in CHB and LF/LC development.

**Fibrosis-associated gene expression in LX2 cells**

According to previous studies, TGF-β1 is the main cytokine involved in hepatic stellate cell (HSC) stimulation and liver fibrosis development (Bi et al., 2012). We stimulated LX2 cells with various TGF-β1 doses and activation durations to determine the best stimulation concentration and time. qRT-PCR was used to evaluate the relative mRNA expression of *COL1* and α-SMA. TGF-β1 stimulation increased *COL1* and α-SMA expression (Fig. 1BC) in a time- and dose-dependent manner; *COL1* and α-SMA mRNA were higher in the 10 ng/ml TGF-β1 group after 48h. As a result, 10 ng/ml TGF-β1 was used to activate LX2 for 48 hours in the next step.
**AGRN, JAG1, CCL5, ID3, CCND1, and CAPN2 mRNA expression levels in LX2 cells**

qRT-PCR was used to evaluate the expression of *AGRN, JAG1, CCL5, ID3, CCND1,* and *CAPN2* mRNA in LX2 cells. LX2 cells were stimulated with 10 ng/ml TGF-β1 over 48 h, with unstimulated cells serving as the control group. As shown in Fig. 1D, the expression levels of *AGRN, JAG1,* and *CCL5* mRNA in the stimulated group were significantly higher than in the unstimulated control group. Up to about a 4-fold increase in *AGRN* gene expression was observed. However, *ID3, CCND1,* and *CAPN2* were downregulated by 25.1%, 48.9%, and 33.2%, respectively, compared with the control group. *AGRN* mRNA was dramatically elevated in activated LX2 cells and exhibited a progressively increasing trend in PBMCs from normal subjects, CHB, and LF/LC patients. This indicates that *AGRN* can be a biomarker of CHB and LF/LC. Therefore, we chose the *AGRN* gene for further investigation.

**AGRN expression is successfully silenced by siRNAs**

With the use of siRNA, genetic knockdown of *AGRN* was carried out to examine the function of *AGRN*. As shown in Figure 2A, 48 h after transfection with siRNA, the 2−ΔΔCt values of *AGRN* calculated by the relative quantitative method for the siRNA-1, siRNA-2, and siRNA-3 groups were 0.31 ± 0.03, 0.31 ± 0.07, and 0.54 ± 0.07, respectively. The expression of *AGRN* mRNA measured by qRT-PCR was considerably lower in all three siRNA groups than in the NC group. However, the differences were not statistically significant between the null, Lipo, and NC groups. These findings show that siRNAs effectively suppress *AGRN* mRNA expression. The siRNA silencing efficiency was calculated using the following formula: siRNA silencing efficiency = (1−*AGRN* expression in the siRNA group/*AGRN* expression in the blank group) × 100%. SiRNA-1 and siRNA-2 exhibited the highest inhibition efficacy, therefore, these were used in subsequent experiments. LX2 cells were transfected with an *AGRN*-targeting siRNA and a negative control siRNA. Then, cells were stimulated with 10 ng/ml TGF-β1 for 24h. As seen in Fig. 2BCD, TGF-β1 dramatically enhanced the expression of *AGRN, COL1,* and *α-SMA* compared with the control group, whether or not a negative control siRNA was transfected. After *AGRN* inhibition by siRNA, the expression of *COL1* and *α-SMA* was markedly reduced in active LX2 cells. Thus, *AGRN* may play a pivotal role in regulating the synthesis and secretion of COL1 and α-SMA in activated LX2 cells and liver fibrosis.

**SiRNA-AGRN suppresses Wnt/β-catenin signaling**

Agrin, a heparan sulfate proteoglycan, is a crucial component of the basal lamina facilitating acetylcholine receptor clustering for proper neuromuscular junction (NMJ) function (Bolliger et al., 2010). It has been demonstrated that *AGRN* can stimulate the classical Wnt/β-catenin signaling pathway to mediate the biological role of NMJ formation (Ohno et al., 2017). The Wnt/β-catenin signaling pathway contributes to liver
fibrosis (Miao et al., 2013). β-catenin, a transcription factor, acts as the main effector of the canonical Wnt signaling pathway. Accumulation of β-catenin in the nucleus activates the canonical Wnt/β-catenin pathway (Schmalhofer et al., 2009). According to our qRT-PCR results (Fig. 2EFG), AGRN inhibition in LX2 cells reduced the expression of β-catenin and downstream c-MYC; concurrently, GSK-3β expression was elevated. GSK-3β, β-catenin, and c-MYC are major signaling proteins in the Wnt/β-catenin signaling pathway. As a result, we anticipated that decreasing AGRN expression would result in decreased ECM expression in activated LX2 cells by blocking the Wnt/β-catenin signaling pathway.

The protein levels of AGRN via ELISA and demographic and clinical characteristics

ELISA was performed to measure protein levels. Our study showed that, compared with the control group, the protein levels of AGRN were significantly increased in the CHB and LF/LC groups. Furthermore, the AGRN protein level was markedly higher in the LF/LC than in the CHB group (Table 2). The demographic and clinical characteristics of patients and healthy subjects are also shown in Table 2. As demonstrated in Table 2, male patients are more common in CHB and LF/LC, particularly LF/LC. Furthermore, age, aspartate aminotransferase (AST), and total bilirubin (TBIL) levels gradually increased across the three groups. However, the expression of white blood cells (WBC), platelet count (PLT), total protein (TP), and albumin (ALB) significantly decreased with disease progression. The differences were statistically significant.

Univariate and multivariate ordinal logistic regression analyses

In order to find important covariates, a univariate regression analysis was performed. Table 3 shows that eight variables, including gender (man), age, WBC, PLT, ALB, AST, TBIL, and AGRN were significantly associated with the incidence of CHB and LF/LC. As TP was not significantly related, it was not included in subsequent analyses. The components showing significant differences in the univariate logistic regression were used in the multivariate logistic regression study. The results showed that PLT (OR = 0.992; 95% CI = 0.989-0.995; P<0.001) and AGRN (OR =3.010; 95% CI =2.455-3.691; P<0.001) were significantly and independently associated with CHB and LF/LC. We developed a regression equation integrating relevant markers to differentiate between healthy subjects, CHB patients, and LF/LC patients: PA = 1.639 - 0.008×PLT + 1.102×AGRN.

Predictive value of the regression model

ROC analysis was used to assess the predictive value of PA in differentiating between healthy, CHB, and LF/LC. As shown in Table 4 and Fig. 3, the PA model's area under the curve (AUC) for predicting CHB was 0.951, which was greater than the APRI and FIB-4 models. It had a sensitivity of 87.0% and a specificity of 91.0%. The optimum
cut-off value for distinguishing CHB patients from healthy subjects was 4.278. In addition, PA was superior to APRI, FIB-4, and even Liver stiffness measurement (LSM) in predicting liver cirrhosis, with AUC values of 0.922, 0.663, 0.725, and 0.768, respectively. The cut-off value was 6.645, with 82.0% sensitivity and 90.0% specificity. Overall, our study found that a unique PA model may be used to distinguish CHB from healthy individuals and LF/LC from CHB. This model is non-invasive, easy to use, and cost-effective.

Discussion

CHB is a global health issue, which affects approximately 257 million people worldwide (Nguyen et al., 2020). In China, it is estimated that there are around 70 million HBV carriers (5-6% prevalence) (Liu et al., 2016), 20 to 30 million people with CHB, 1 million with liver cirrhosis, and 0.3 million with hepatocellular carcinoma caused by HBV (Shan et al., 2017). HSC proliferation is associated with the production of collagen and other ECM components. Local collagen deposition leads to advanced liver fibrosis, pseudolobule formation, and eventually cirrhosis. The continuous inflammatory microenvironment, which accelerates the repair and proliferation of hepatocytes, can promote the occurrence of tumors (Llovet et al., 2016; D'Amico et al., 2018).

Given the serious public health concern of complications related to hepatitis B, accurate diagnosis of HBV-associated liver disease is critical. Although liver biopsy remains the gold standard for diagnosing CHB and LF/LC, there are still major concerns, such as sampling error, high bleeding risk, heavy medical burden, interobserver discrepancy, and inability to be repeated, limiting its widespread use in clinical practice (Lok et al., 2009; Venkatesh et al., 2013). Biological markers, such as proteins and DNA, discovered in tissues and bodily fluids (e.g., blood and urine), typically serve as indicators of therapeutic response and disease severity (Birkó et al., 2020). Recently, the non-invasive assessment of HBV-associated liver disease has grown rapidly owing to the stability, wide distribution, and ease of detection of serum biomarkers.

Previous transcriptome sequencing and bioinformatics results from our research group indicated that the AGRN, JAG1, CCL5, ID3, CCND1, and CAPN2 genes were differentially expressed in CHB and LF/LC patients compared with healthy controls, and gradually increased with disease progression. In the current investigation, we initially confirmed the expression trend of six genes in PBMCs from healthy participants, CHB patients, and LF/LC patients. We discovered that only AGRN gene expression steadily and significantly increased in all three groups. Cell models of HBV infection and replication in vitro are important tools for studying HBV-related liver diseases. However, there are many limitations of in vitro HBV models established by laboratories at home and abroad, such as low actual infection efficiency, low level of virological indicators after replication, long culture and differentiation cycle, and high infective dose, which greatly limit the application of HBV-related cell models. LX-2 used in this study are immortalized cell lines. Under the stimulation of various factors, HSCs are transformed from the static cell to the myofibroblast phenotype with proliferation, fibroblast, and contraction, which is the activated HSCs (Geerts 2001). TGF-β has the most significant effect on activating HSC-inducing factors (Kaimori et al., 2007; Nguyen et al., 2007;
Zhang et al., 2014; Khanizadeh et al., 2015). Meanwhile, the expression of AGRN mRNA was also significantly increased in TGF-β1-activated LX2 cells. In addition, ELISA was used to detect AGRN protein in the three groups, which also showed a progressively increasing trend. These findings imply that AGRN may have a role in the progression of CHB and LF/LC after HBV infection.

AGRN, a heparan sulfate proteoglycan (HSPG), is a component of the ECM (Neill et al., 2015), which plays an important role in skeletal muscle development, NMJ formation, hematopoiesis, and inflammation (Bruno et al., 1995; Jurdana et al., 2009; Zong et al., 2013). It is expressed in the hepatic bile duct and vascular basement membrane of the normal liver (Tátrai et al., 2009), which is a specific and sensitive biomarker of hepatocellular carcinoma due to its expression in the microvasculature; however, it has rarely been studied in CHB and LF/LC (Tátrai et al., 2009).

Currently known Agrin receptors include MuSK-Lrp4, integrin, dystroglycan 1, and α3 sodium and potassium pump (Zhang et al., 2008). When Agrin interacts with MuSK-Lrp4, it can activate the classical Wnt/β-catenin pathway (Barik et al., 2014). Multiple studies have reported that the abnormal expression of the Wnt/β-catenin signaling pathway is involved in multiple processes of liver disease pathophysiology, such as hepatocyte proliferation, HSC activation, liver fibrosis, cirrhosis, focal nodular hyperplasia, and even the occurrence and development of liver tumors (Perugorria et al., 2019; Rao et al., 2019; Rong et al, 2019; Zhang et al., 2020).

Our results showed that AGRN inhibition by siRNA in activated LX2 cells significantly decreases COL1 and α-SMA expression. Further experiments indicated a significant downregulation of the β-catenin gene and its downstream gene c-MYC, with a notable upregulation of GSK-3β expression after AGRN inhibition. β-catenin, a cytoskeletal protein, serves as a crucial signaling molecule in the regulation of the classical Wnt/β-catenin pathway. When this pathway is inactivated, β-catenin is typically phosphorylated and degraded by the GSK-3β complex. GSK-3β functions as an essential negative regulator and its downregulation reflects the activation of the Wnt/β-catenin signaling pathway (Wu et al., 2010). The Wnt/β-catenin pathway promotes the transcription of c-MYC (Shi et al., 2007), and is closely linked to liver fibrosis, suggesting that silencing AGRN via siRNA may reduce the development of liver fibrosis by inhibiting the Wnt/β-catenin signaling pathway. Therefore, AGRN can serve as a new therapeutic target for the prevention and treatment of liver fibrosis and may offer fresh perspectives on its clinical management.

Over the past decade, a number of non-invasive techniques, including APRI and FIB-4, have been used to predict liver fibrosis (Xiao et al., 2015). FibroScan is a practical and repeatable non-invasive detection method that is frequently used to identify liver fibrosis (Huang et al., 2021). The ideal non-invasive technique should be straightforward, affordable, trustworthy, and accurate. In this study, a novel model called PA was developed based on PLT and AGRN. Compared to APRI, FIB-4, and LSM, PA had the highest AUC of HBV-related liver diseases and the highest sensitivity and specificity. In the diagnosis of LF/LC, the sensitivity and specificity of the PA model are greater than those of LSM, indicating that the model has a superior diagnostic yield. The PA model can serve as a new reference index for evaluating CHB and LF/LC since it is non-invasive, accurate, and reproducible.
However, there were certain restrictions in our study. First, the sample size of the study was relatively small, and the data included in the present study were from a single center. An optimized cooperative multicenter study is required to verify the model. Furthermore, patients with CHB and LF/LC were not divided based on the use of antiviral drugs. Aside from that, more functional studies are needed to elucidate the function of AGRN in chronic liver disease in vitro and in vivo.

In conclusion, the current study demonstrated that AGRN might be a potential plasma biomarker for the diagnosis of CHB, and the PA model established achieved higher accuracy and better performance than APRI and FIB-4 in differentiating HBV-related chronic hepatitis and liver fibrosis/cirrhosis.

Declarations

Funding

This project was supported by the Key Research and Development Program of Hebei Province in 2019 (No. 19277779D); the introduction of foreign intelligence program in Hebei Province in 2020; and the project of provincial subsidy Fund (Construction of key traditional Chinese medicine Disciplines) for inheritance and development of traditional Chinese medicine in 2022.

Competing interests

We declare that we have no financial or personal relationships with other people or organizations that can inappropriately influence our work.

Ethics approval and informed consent

Each participant provided written informed permission, which was also authorized by the Third Hospital of Hebei Medical University's local ethics council.

Data availability

The authors affirm that all pertinent information supporting the conclusions drawn from this investigation is contained in the article and its Supplementary Information files, and, upon reasonable request, is available directly from the corresponding author.

Authors' contributions

Design and writing the article: Rong Ai; cell experiment: Lu Li, Xiwei Yuan; data collection: Chen Dong, Yao Dou, Mengmeng Hou; statistical analysis: Dandan Zhao, Shiming Dong; literature review and evaluation: Tongguo Miao, Weiwei Guan; critical
Figures

Fig. 1 (A) qRT-PCR validation of differentially expressed genes in the transcriptome sequencing of human PBMCs (n=20). Data are shown as mean ± SD. The results were normalized based on the housekeeping gene GAPDH. * indicates P<0.05, and ** indicates P<0.01. The expression of COL1 and α-SMA mRNA in LX2 cells stimulated by TGF-β1 at different time intervals and concentrations using qRT-PCR. (B) LX2 cells were stimulated with TGF-β1 (10 ng/ml) for 0, 12, 24, and 48h, respectively. (C) LX2 cells were stimulated with TGF-β1 (0 ng/ml, 2 ng/ml, 5 ng/ml, and 10 ng/ml) for 48 h. Data are shown as mean ± SD. The results were normalized based on the housekeeping gene GAPDH. * indicates P<0.05, and ** indicates P<0.01. (D) qRT-PCR validation of differentially expressed genes in the transcriptome sequencing in LX2 cells. Cells were stimulated with TGF-β1 (10 ng/ml) for 48 h. Cells were stimulated without TGF-β1 as control. Data are shown as the mean ± SD. The results were normalized based on the housekeeping genes GAPDH. ** indicates P<0.01.

Fig. 2 Effect of gene-specific AGRN siRNA on the fibrotic markers of LX2 cells. (A) Comparison of AGRN mRNA expression levels among siRNA, Lipo, and Null groups after transfection with three siRNA-AGRN oligonucleotide sequences and siRNA-NC. (B) qRT-PCR detected the expression of AGRN of each experimental group at 24 h after 10 ng/ml TGF-β1 treatment. (C) and (D) The effect of siRNA-AGRN knockdown on the expression of the fibrotic markers COL1 (C) and α-SMA (D) was determined using qRT-PCR at 24h after 10 ng/ml TGF-β1 treatment. * indicates P<0.05, and ** indicates P<0.01. (E, F, G) Effect of silencing AGRN by siRNA on major genes of the canonical Wnt/β-catenin signaling pathway in LX2 cells. Data are shown as mean ± SD. qRT-PCR results were normalized to the housekeeping gene GAPDH. ** indicates P<0.01.

Fig. 3 Clinical characteristics and laboratory parameters of the three groups were compared. The multivariate ordinal logistic regression analysis was used to find the best predictors. PLT (A) and plasma levels of AGRN (B) were assessed and compared between healthy controls, CHB patients, and LF/LC patients. The diagnostic performance of the PA model is presented. (C) ROC curves of the PA model, FIB-4, and APRI for distinguishing CHB from CONTROL. (D) ROC curves of the PA model, LSM, FIB-4, and APRI for differentiating LF/LC from CHB. *P<0.05 versus healthy controls; #P<0.05 versus CHB patients.
<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Sequence (5’ to 3’)</th>
<th>Reverse Sequence (5’ to 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGRN</td>
<td>GTCCCTGCGTCTGCAAGAAGAG</td>
<td>CTCGCATTTCGTTGCTGTAGGG</td>
</tr>
<tr>
<td>JAG1</td>
<td>GTCCATGCAGAACGTGAACG</td>
<td>GCGGGACTGATACTCCTTTGA</td>
</tr>
<tr>
<td>CCL5</td>
<td>CCAGCAGTCGTCTTTTGTCAC</td>
<td>CTCTGGTTGCGACACACCTTT</td>
</tr>
<tr>
<td>ID3</td>
<td>GAGAGGCACTCAGCTTAGCC</td>
<td>TCTTTTTGTCGTGGAGATGAC</td>
</tr>
<tr>
<td>CCND1</td>
<td>GCTGCAGAAGTGGAACCATC</td>
<td>CCTCCTTCTGCACACATTTGGA</td>
</tr>
<tr>
<td>CAPN2</td>
<td>GTTCTGGCAATACGGCGAGT</td>
<td>CTTGGCTGAATGCGACAAAGA</td>
</tr>
<tr>
<td>COL1</td>
<td>GAGGGCCAAGACGAAAGACATC</td>
<td>CAGATCACGTCATCGCACAAC</td>
</tr>
<tr>
<td>α-SMA</td>
<td>AAAAGACAGCTACGTGGGTGA</td>
<td>GCCATGTCTATCGGGGTACTTC</td>
</tr>
<tr>
<td>β-catenin</td>
<td>AAAGCGGCTGTAGTGACTCCGTG</td>
<td>CGAGTCATTGCATACTGTCATCCAT</td>
</tr>
<tr>
<td>GSK-3β</td>
<td>GGCAGCATGAAAGTTAGCACAGA</td>
<td>GCCGACCAGTTCTCCTGAACTC</td>
</tr>
<tr>
<td>c-MYC</td>
<td>GGCTCCTGGCAAAAAGGTTCA</td>
<td>CTGCAGTAGTTGTGCTGATGT</td>
</tr>
<tr>
<td>GAPDH</td>
<td>GGAGCGAGATCCCTCTCCAATA</td>
<td>GGCTGTTGTCATACTTCTCATGG</td>
</tr>
<tr>
<td>AGRN-siRNA-1</td>
<td>GCACGUAUGACAGUGAUUGTT</td>
<td>CAAUCACGUGCUACGUGGCTT</td>
</tr>
<tr>
<td>AGRN-siRNA-2</td>
<td>GCCAGGAGAAUGUCUUCAATT</td>
<td>UUGAAGACAUUCUCUGGCTT</td>
</tr>
<tr>
<td>AGRN-siRNA-3</td>
<td>GCGGUACUUGAAGGGCAATT</td>
<td>UUGCUCUUCUCAGUACCCGT</td>
</tr>
<tr>
<td>AGRN-siRNA-NC</td>
<td>UUCUCCGAAACGUGUCAGUTT</td>
<td>ACGUGACACGUUCGGAAGAATT</td>
</tr>
<tr>
<td>Variables</td>
<td>CONTROL (N=100)</td>
<td>CHB (N=100)</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Gender (male), n (%)</td>
<td>45 (45.0)</td>
<td>65 (65.0) *</td>
</tr>
<tr>
<td>Age (years)</td>
<td>33.0 (27.0-41.0)</td>
<td>42.0 (34.0-52.0) *</td>
</tr>
<tr>
<td>WBC (10^9/L)</td>
<td>5.9 (5.1-7.4)</td>
<td>4.9 (4.1-6.0) *</td>
</tr>
<tr>
<td>RBC (10^{12}/L)</td>
<td>4.6 (4.5-5.0)</td>
<td>4.7 (4.3-5.1)</td>
</tr>
<tr>
<td>HGB (g/L)</td>
<td>140.9 (133.2-153.9)</td>
<td>144.0 (130.0-155.0)</td>
</tr>
<tr>
<td>MCV (fL)</td>
<td>—</td>
<td>91.9 (88.7-94.6)</td>
</tr>
<tr>
<td>PLT (10^9/L)</td>
<td>232.8 (201.6-264.9)</td>
<td>200.6 (148.0-241.0) *</td>
</tr>
<tr>
<td>TP (g/L)</td>
<td>73.6 (71.8-76.5)</td>
<td>72.3 (64.8-75.4) *</td>
</tr>
<tr>
<td>ALB (g/L)</td>
<td>45.8 (43.2-48.2)</td>
<td>45.0 (38.6-47.9) *#</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>17.0 (13.0-24.3)</td>
<td>39.0 (20.0-118.0) *</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>17.5 (15.0-21.0)</td>
<td>27.0 (20.0-70.0) *</td>
</tr>
<tr>
<td>TBIL (µmol/L)</td>
<td>16.2 (12.6-18.9)</td>
<td>17.0 (13.4-24.5) *</td>
</tr>
<tr>
<td>DBIL (µmol/L)</td>
<td>—</td>
<td>8.3 (5.0-10.9)</td>
</tr>
<tr>
<td>ALP (U/L)</td>
<td>—</td>
<td>85.0 (66.0-103.0)</td>
</tr>
<tr>
<td>GGT (U/L)</td>
<td>—</td>
<td>60.0 (26.0-136.0)</td>
</tr>
<tr>
<td>CHE (U/L)</td>
<td>—</td>
<td>8.4±3.0</td>
</tr>
<tr>
<td>TBA (µmol/L)</td>
<td>—</td>
<td>8.2 (3.4-20.1)</td>
</tr>
<tr>
<td>CK (U/L)</td>
<td>—</td>
<td>62.7 (45.1-90.6)</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>—</td>
<td>193.1±85.7</td>
</tr>
<tr>
<td>TCHO (mmol/L)</td>
<td>—</td>
<td>4.1 (3.6-4.7)</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>—</td>
<td>1.2 (0.7-1.7)</td>
</tr>
<tr>
<td>GLU (mmol/L)</td>
<td>5.0 (4.5-5.5)</td>
<td>5.4 (4.9-5.9) *</td>
</tr>
<tr>
<td>Urea (mmol/L)</td>
<td>4.6 (3.6-5.4)</td>
<td>4.4 (3.7-5.4)</td>
</tr>
<tr>
<td>CREA (µmol/L)</td>
<td>64.3 (55.6-77.3)</td>
<td>66.3 (55.0-77.4)</td>
</tr>
<tr>
<td>URIC (µmol/L)</td>
<td>289.0 (239.5-353.5)</td>
<td>322.0 (261.0-389.0)</td>
</tr>
<tr>
<td></td>
<td>Healthy Control</td>
<td>CHB</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-----------------</td>
<td>-----</td>
</tr>
<tr>
<td>Ca (mmol/L)</td>
<td>2.4±0.1</td>
<td>2.3±0.2</td>
</tr>
<tr>
<td>PHOS (mmol/L)</td>
<td>1.1±0.2</td>
<td>1.1±0.2</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>2.2 (1.6-3.2)</td>
<td>1.9 (1.6-3.4)</td>
</tr>
<tr>
<td>PT (s)</td>
<td>12.0 (11.0-13.0)</td>
<td>12.0 (11.2-13.5)</td>
</tr>
<tr>
<td>INR</td>
<td>1.1 (1.0-1.2)</td>
<td>1.0 (1.0-1.2)</td>
</tr>
<tr>
<td>HBsAg (log_{10} IU/mL)</td>
<td>3.1 (2.4-4.0)</td>
<td>2.8 (2.3-3.2)</td>
</tr>
<tr>
<td>HBVDNA (log_{10} IU/mL)</td>
<td>2.7 (1.3-6.0)</td>
<td>2.3 (1.3-5.0)</td>
</tr>
<tr>
<td>AFP (ng/mL)</td>
<td>3.8 (2.6-13.7)</td>
<td>4.5 (2.2-26.9)</td>
</tr>
<tr>
<td>Ferritin (ng/mL)</td>
<td>128.4 (39.0-365.4)</td>
<td>157.2 (65.7-267.6)</td>
</tr>
<tr>
<td>LSM (kPa)</td>
<td>7.6 (5.3-10.9)</td>
<td>13.7 (10.3-19.3)</td>
</tr>
<tr>
<td>FIB-4</td>
<td>0.5 (0.4-0.6)</td>
<td>1.1 (0.7-2.1)</td>
</tr>
<tr>
<td>APRI</td>
<td>0.2 (0.1-0.3)</td>
<td>0.4 (0.2-1.1)</td>
</tr>
<tr>
<td>AGRN (ng/mL)</td>
<td>2.8 (2.1-3.5)</td>
<td>4.8 (4.0-5.5)</td>
</tr>
</tbody>
</table>

**Notes:** *P*<0.05 vs. healthy control; #*P*<0.05 vs. chronic hepatitis B.

Abbreviations: WBC: white blood cell; RBC: red blood cell; HGB: hemoglobin; MCV: mean corpuscular volume; PLT: platelet; TP: total protein; ALB: albumin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; DBIL: direct bilirubin; ALP: alkaline phosphatase; GGT: gamma-glutamyl transferase; CHE: cholinesterase; TBA: total bile acid; CK: creatine kinase; LDH: lactate dehydrogenase; TCHO: total cholesterol; TG: triglyceride; GLU: glucose; CREA: creatinine; Ca: calcium; PHOS: phosphorus; CRP: C-reactive protein; PT: prothrombin time; INR: international normalized ratio; HBsAg: hepatitis B surface antigen; HBVDNA: hepatitis B virus deoxyribonucleic acid; AFP: alpha fetoprotein; LSM: liver stiffness measurement; FIB-4: fibrosis index based on the 4 factors; APRI: AST-to-PLT ratio index; AGRN: agrin; CHB: chronic hepatitis B; LF/LC: liver fibrosis/liver cirrhosis.
Table 3. Univariate and multivariate ordinal logistic analyses for the variables

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariate ordinal logistic analyses</th>
<th>Multivariate ordinal logistic analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td>Gender (male), n (%)</td>
<td>0.402 (0.259-0.624)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Age (years)</td>
<td>1.069 (1.050-1.090)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>WBC (10^6/L)</td>
<td>0.797 (0.733-0.866)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>PLT (10^9/L)</td>
<td>0.984 (0.981-0.988)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>TP (g/L)</td>
<td>1.000 (0.999-1.002)</td>
<td>0.422</td>
</tr>
<tr>
<td>ALB (g/L)</td>
<td>0.882 (0.849-0.918)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>1.006 (1.003-1.010)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>TBIL (µmol/L)</td>
<td>1.017 (1.008-1.025)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>AGRN (ng/mL)</td>
<td>9.161 (6.246-13.437)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td></td>
<td>3.010 (2.455-3.691)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

Abbreviations: WBC: white blood cell; PLT: platelet; TP: total protein; ALB: albumin; AST: aspartate aminotransferase; TBIL: total bilirubin; AGRN: agrin.
Table 4. Comparison of the diagnostic performance of FIB-4, APRI, LSM, and PA in patients with CHB and LF/LC

<table>
<thead>
<tr>
<th>Variables</th>
<th>AUC</th>
<th>Cut-off</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Youden index</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHB</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIB-4</td>
<td>0.775</td>
<td>0.989</td>
<td>54.5</td>
<td>91.0</td>
<td>0.456</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>APRI</td>
<td>0.803</td>
<td>0.232</td>
<td>78.0</td>
<td>73.0</td>
<td>0.510</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>PA(^{*,$})</td>
<td>0.951</td>
<td>4.278</td>
<td>87.0</td>
<td>91.0</td>
<td>0.780</td>
<td>—</td>
</tr>
<tr>
<td>LSM</td>
<td>0.768</td>
<td>10.93</td>
<td>71.3</td>
<td>76.3</td>
<td>0.476</td>
<td>0.0002</td>
</tr>
<tr>
<td><strong>LF/LC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIB-4</td>
<td>0.725</td>
<td>1.446</td>
<td>80.0</td>
<td>63.6</td>
<td>0.436</td>
<td>0.0001</td>
</tr>
<tr>
<td>APRI</td>
<td>0.663</td>
<td>0.479</td>
<td>75.0</td>
<td>61.0</td>
<td>0.360</td>
<td>0.0001</td>
</tr>
<tr>
<td>PA(^{*,$})</td>
<td>0.922</td>
<td>6.645</td>
<td>82.0</td>
<td>90.0</td>
<td>0.720</td>
<td>—</td>
</tr>
</tbody>
</table>

Notes: \(^{*}\)P<0.05 vs LSM in AUC; \(^{\#}\)P<0.05 vs FIB-4 in AUC; \(^{\$}\)P<0.05 vs. APRI in AUC.

Abbreviations: LSM: liver stiffness measurement; FIB-4: fibrosis index based on the 4 factors; APRI: AST-to-PLT ratio index; PA: the model based on PLT and AGRN; CHB: chronic hepatitis B; LF/LC: liver fibrosis/liver cirrhosis.
References:


**HISTOLOGY AND HISTOPATHOLOGY**

### AGRN Expression

- **A:** Relative mRNA expression of AGRN across different groups.
  - siRNA-NC
  - siRNA-1
  - siRNA-2
  - siRNA-3
  - Lipo
  - Null

### β-catenin Expression

- **E:** Relative mRNA expression of β-catenin.
  - siRNA-NC
  - siRNA-AGRN

### GSK-3β Expression

- **F:** Relative mRNA expression of GSK-3β.
  - siRNA-NC
  - siRNA-AGRN

### c-MYC Expression

- **G:** Relative mRNA expression of c-MYC.
  - siRNA-NC
  - siRNA-AGRN